Cargando…
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
BACKGROUND: Mesothelin (MSLN) is a classic tumor-associated antigen that is expressed in lung cancer and many other solid tumors. However, MSLN is also expressed in normal mesothelium which creates a significant risk of serious inflammation for MSLN-directed therapeutics. We have developed a dual-re...
Autores principales: | Tokatlian, Talar, Asuelime, Grace E, Mock, Jee-Young, DiAndreth, Breanna, Sharma, Shruti, Toledo Warshaviak, Dora, Daris, Mark E, Bolanos, Kristian, Luna, Breanna L, Naradikian, Martin S, Deshmukh, Kiran, Hamburger, Agnes E, Kamb, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804709/ https://www.ncbi.nlm.nih.gov/pubmed/35091455 http://dx.doi.org/10.1136/jitc-2021-003826 |
Ejemplares similares
-
Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity
por: Tokatlian, Talar, et al.
Publicado: (2022) -
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
por: Anderson, Kristin G, et al.
Publicado: (2022) -
Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023) -
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
por: Kuo, Yi-Chiu, et al.
Publicado: (2022) -
Robust In Vitro Pharmacology of Tmod, a Synthetic Dual-Signal Integrator for Cancer Cell Therapy
por: Manry, Diane, et al.
Publicado: (2022)